Who are Solvetx's investors?

Solvetx's investors include Decheng Capital, Matrix Capital Management, Yosemite, B Capital Group, B4 Capital.

Solvetx

5 known investors

Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection. The company has two lead programs in Phase 1 clinical development.

BiotechDeep TechHealthtechin /matrix-capital-management-llc

Founders & leadership

David JohnsonChief Executive Officer

Clayton KnoxPresident

Katti JessenSVP, Translational Sciences

Yakov KoganHead of Operations

Brian LannuttiResearch & Development Leadership

Langdon MillerClinical Development Leadership

Jeff SchaalRadiopharmaceutical Discovery & Development Lead

Mike SunCMC Leadership

Jeff WatkinsProtein Engineering Leadership

Jon WilliamsSVP of Finance

Investors · 5

Decheng Capital✓ verifiedMenlo Park

Matrix Capital Management✓ verifiedPortsmouth

Yosemite✓ verifiedSan Francisco

B Capital GroupManhattan Beach · $10M – $50M

B4 Capital$10M – $50M

Competitors · 3

by search overlap

Solu32 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Bioworld24 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Applied Therapeutics21 shared keywordsApplied Therapeutics is a biopharmaceutical company developing treatments for rare diseases, with a portfolio focused on Classical Galactosemia and CMT-SORD. Its lead investigational drug, govorestat, targets disease pathways such as galactitol and sorbitol reduction.

Companies competing with Solvetx for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Solvetx do?: Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection. The company has two lead programs in Phase 1 clinical development.
Who are Solvetx's investors?: Solvetx's investors include Decheng Capital, Matrix Capital Management, Yosemite, B Capital Group, B4 Capital.